heart iconheart icon
Skip to content

News Releases

 
News Releases
  Date Title and Summary View
Feb 8, 2018
Feb 8, 2018
Feb 7, 2018
NEW BRUNSWICK, N.J., Feb. 7, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, Feb. 21, at the Lotte New York Palace in New York City.  Dominic Caruso, Executive Vice President, Chief Financial Officer will represent the Company in a session scheduled at 1:...
Jan 31, 2018
NEW BRUNSWICK, N.J., Jan. 31, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Leerink Partners 7th Annual Global Healthcare Conference on Wednesday, Feb. 14, at Lotte New York Palace, NY.  Dominic Caruso, Executive Vice President, Chief Financial Officer will represent the Company in a session scheduled at 9:30 a.m. (East...
Jan 25, 2018
Jan 23, 2018
NEW BRUNSWICK, N.J., Jan. 23, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $20.2 billion for the fourth quarter of 2017, an increase of 11.5% as compared to the fourth quarter of 2016. Operational sales results increased 9.4% and the positive impact of currency was 2.1%. Domestic sales increased 9.8%. International sa...
Jan 2, 2018
NEW BRUNSWICK, N.J., Jan. 2, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2018 of $0.84 per share on the company's common stock. The dividend is payable on March 13, 2018 to shareholders of record at the close of business on February 27, 2018. Th...
Dec 21, 2017
HORSHAM, Pa., Dec. 21, 2017 /PRNewswire/ -- Janssen Biotech, Inc. ("Janssen"), a Janssen Pharmaceutical Company of Johnson & Johnson, announced today that it has entered into a worldwide collaboration and license agreement with Legend Biotech USA Inc. and Legend Biotech Ireland Limited ("Legend"), subsidiaries of Genscript Biotech Corporation, to d...
Dec 21, 2017
HORSHAM, Pa., Dec. 21, 2017 /PRNewswire/ -- Janssen Biotech, Inc. (Janssen) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for the New Drug Application (NDA) for apalutamide, an investigational, next-generation oral androgen receptor (AR) inhibitor for the treatment of men with non-metastati...
Dec 19, 2017
NEW BRUNSWICK, N.J., Dec. 19, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 36th Annual JP Morgan Health Care Conference on Monday, Jan. 8, at the Westin St. Francis in San Francisco.  Alex Gorsky, Chairman and Chief Executive Officer, will represent the Company in a session scheduled at 2:30 p.m. (Pacific Time)/5:30 p....
Page: FirstPrevious
3
... NextLast
= add release to Briefcase